Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province, College of Optoelectronic Engineering, Shenzhen University, Shenzhen, China.
Biophotonics Research Laboratory, Center for Interdisciplinary Biomedical Education and Research, College of Mathematics and Science, University of Central Oklahoma, Edmond, Oklahoma.
Clin Cancer Res. 2018 Nov 1;24(21):5335-5346. doi: 10.1158/1078-0432.CCR-18-1126. Epub 2018 Aug 1.
To develop a synergistic combination therapy for advanced pancreatic cancer, using local phototherapy and immunotherapy, and to determine the efficacy and mechanism of the novel combination therapy using a highly metastatic pancreatic tumor model in mice. Mice bearing Panc02-H7 pancreatic tumors (both subcutaneous and orthotopic) were treated with noninvasive or interventional photothermal therapy, followed by local application of an immunoadjuvant. Tumor growth and animal survival were assessed. Immune cell populations within spleen and tumors were evaluated by FACS and IHC, and cytokine levels were determined by ELISA. Up to 75% of mice bearing subcutaneous tumors treated with combination therapy had complete tumor regression. Local photothermal therapy exposed/released damage-associated molecular patterns, which initiated an immunogenic tumor cell death, resulting in infiltration of antigen-presenting cells and Th1 immunity. Concomitant application of immunoadjuvant amplified Th1 immunity, especially the tumor-specific cytotoxic T lymphocyte response, with increased quantity and quality of T cells. Combination therapy also induced tumor-specific immune memory, as demonstrated by resistance to tumor rechallenge and production of memory T cells. For the treatment of orthotopic tumor, the combination therapy significantly reduced the primary tumors and metastases, and prolonged the animal survival time. This study indicated that combination of local phototherapy and immunotherapy induced a systemic immunity against established tumors and metastases in an aggressive, preclinical pancreatic tumor model, leading to a potential clinical method for patients with advanced pancreatic cancer. .
为了开发一种用于治疗晚期胰腺癌的协同联合治疗方法,利用局部光疗和免疫疗法,并使用高度转移性胰腺癌小鼠模型来确定新型联合治疗的疗效和机制。在携带 Panc02-H7 胰腺肿瘤(皮下和原位)的小鼠中进行非侵入性或介入性光热疗法,然后局部应用免疫佐剂。评估肿瘤生长和动物存活率。通过 FACS 和 IHC 评估脾和肿瘤内的免疫细胞群,并通过 ELISA 测定细胞因子水平。接受联合治疗的患有皮下肿瘤的小鼠中,多达 75%的小鼠完全消退了肿瘤。局部光热疗法使损伤相关分子模式暴露/释放,引发免疫原性肿瘤细胞死亡,导致抗原呈递细胞浸润和 Th1 免疫。同时应用免疫佐剂增强了 Th1 免疫,特别是肿瘤特异性细胞毒性 T 淋巴细胞反应,增加了 T 细胞的数量和质量。联合治疗还诱导了肿瘤特异性免疫记忆,如对肿瘤再挑战的抵抗和记忆 T 细胞的产生所证明的那样。对于原位肿瘤的治疗,联合治疗显著减少了原发性肿瘤和转移瘤,并延长了动物的存活时间。这项研究表明,局部光疗和免疫疗法的联合使用在侵袭性的临床前胰腺癌模型中诱导了针对已建立的肿瘤和转移瘤的全身性免疫反应,为晚期胰腺癌患者提供了一种潜在的临床方法。